- Home
- Publications
- Publication Search
- Publication Details
Title
Favipiravir in Therapy of Viral Infections
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 10, Issue 2, Pages 273
Publisher
MDPI AG
Online
2021-01-14
DOI
10.3390/jcm10020273
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
- (2020) Kimiyasu Shiraki et al. PHARMACOLOGY & THERAPEUTICS
- Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection
- (2020) Mutsuyo Takayama-Ito et al. Frontiers in Microbiology
- Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
- (2020) Qingxian Cai et al. Engineering
- Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis
- (2020) Wei Liu et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
- (2020) Andrey A Ivashchenko et al. CLINICAL INFECTIOUS DISEASES
- A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19
- (2020) Yohei Doi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
- (2020) Yan Lou et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis
- (2020) Dhan Bahadur Shrestha et al. Virology Journal
- Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
- (2020) Zarir F. Udwadia et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Lethal mutagenesis of Rift Valley fever virus induced by favipiravir
- (2019) Belén Borrego et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Anti-Ebola therapy for patients with Ebola virus disease: a systematic review
- (2019) James S. Lee et al. BMC INFECTIOUS DISEASES
- Influenza virus polymerase inhibitors in clinical development
- (2019) Frederick G. Hayden et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Synergistic lethal mutagenesis of hepatitis C virus
- (2019) Isabel Gallego et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection
- (2019) Yeming Wang et al. JOURNAL OF INFECTIOUS DISEASES
- Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference
- (2018) Jennifer L. McKimm-Breschkin et al. ANTIVIRAL RESEARCH
- Determining the Mutation Bias of Favipiravir in Influenza Virus Using Next-Generation Sequencing
- (2018) Daniel H. Goldhill et al. JOURNAL OF VIROLOGY
- Mutagenesis in Norovirus in Response to Favipiravir Treatment
- (2018) Christopher Ruis et al. NEW ENGLAND JOURNAL OF MEDICINE
- The mechanism of resistance to favipiravir in influenza
- (2018) Daniel H. Goldhill et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase
- (2017) Rana Abdelnabi et al. JOURNAL OF VIROLOGY
- Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
- (2017) Yousuke FURUTA et al. PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Favipiravir can evoke lethal mutagenesis and extinction of foot-and-mouth disease virus
- (2017) Ana Isabel de Avila et al. VIRUS RESEARCH
- Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted
- (2017) Thi Huyen Tram Nguyen et al. PLoS Neglected Tropical Diseases
- Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses
- (2016) Jennifer L. McKimm-Breschkin et al. ANTIVIRAL RESEARCH
- Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)—Sierra Leone, 2014
- (2016) Chang-Qing Bai et al. CLINICAL INFECTIOUS DISEASES
- Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials
- (2016) Vincent Madelain et al. CLINICAL PHARMACOKINETICS
- An experimental evaluation of drug-induced mutational meltdown as an antiviral treatment strategy
- (2016) Claudia Bank et al. EVOLUTION
- Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice
- (2016) Bindumadhav M. Marathe et al. Scientific Reports
- Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
- (2016) Ana I. de Ávila et al. PLoS One
- Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis
- (2015) Kentaro Yamada et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever
- (2015) Lisa Oestereich et al. JOURNAL OF INFECTIOUS DISEASES
- Dose regimen of favipiravir for Ebola virus disease
- (2015) France Mentré et al. LANCET INFECTIOUS DISEASES
- Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers
- (2015) Michael Jacobs et al. LANCET INFECTIOUS DISEASES
- The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset
- (2015) David Safronetz et al. Scientific Reports
- Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model
- (2014) Lisa Oestereich et al. ANTIVIRAL RESEARCH
- Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model
- (2014) Sophie J. Smither et al. ANTIVIRAL RESEARCH
- Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment
- (2014) Dionna Scharton et al. ANTIVIRAL RESEARCH
- Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral
- (2014) Leen Delang et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Characterization of Susceptibility Variants of Influenza Virus Grown in the Presence of T-705
- (2014) Tohru Daikoku et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Favipiravir: A New Medication for the Ebola Virus Disease Pandemic
- (2014) Takashi Nagata et al. Disaster Medicine and Public Health Preparedness
- Generation and characterization of influenza A viruses with altered polymerase fidelity
- (2014) Peter P. H. Cheung et al. Nature Communications
- Evaluation of Antiviral Efficacy of Ribavirin, Arbidol, and T-705 (Favipiravir) in a Mouse Model for Crimean-Congo Hemorrhagic Fever
- (2014) Lisa Oestereich et al. PLoS Neglected Tropical Diseases
- Favipiravir elicits antiviral mutagenesis during virus replication in vivo
- (2014) Armando Arias et al. eLife
- Mechanism of Action of T-705 Ribosyl Triphosphate against Influenza Virus RNA Polymerase
- (2013) Hidehiro Sangawa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antiviral Efficacy of Favipiravir against Two Prominent Etiological Agents of Hantavirus Pulmonary Syndrome
- (2013) David Safronetz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Favipiravir (T-705), a novel viral RNA polymerase inhibitor
- (2013) Yousuke Furuta et al. ANTIVIRAL RESEARCH
- T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro
- (2013) T. Baranovich et al. JOURNAL OF VIROLOGY
- Characterization of H7N9 influenza A viruses isolated from humans
- (2013) Tokiko Watanabe et al. NATURE
- The Ambiguous Base-Pairing and High Substrate Efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards Influenza A Virus Polymerase
- (2013) Zhinan Jin et al. PLoS One
- Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice
- (2012) E. Bart Tarbet et al. ANTIVIRAL RESEARCH
- T-705 (Favipiravir) Inhibition of Arenavirus Replication in Cell Culture
- (2010) Michelle Mendenhall et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses
- (2010) K. Sleeman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effects of the Combination of Favipiravir (T-705) and Oseltamivir on Influenza A Virus Infections in Mice
- (2009) D. F. Smee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models
- (2009) Brian B. Gowen et al. ANTIVIRAL RESEARCH
- In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses
- (2009) Yasushi Itoh et al. NATURE
- T-705 (favipiravir) activity against lethal H5N1 influenza A viruses
- (2009) M. Kiso et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activity of T-705 in a Hamster Model of Yellow Fever Virus Infection in Comparison with That of a Chemically Related Compound, T-1106
- (2008) J. G. Julander et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started